NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Dabrafenib in combination with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID3851]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • Novartis pharmaceuticals (dabrafenib and trametinib) Patient/carer groups • Asthma and Lung UK • Black Health Agency • British Lung Foundation • Cancer Black Care • Cancer Equality • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Roy Castle Lung Cancer Foundation • Ruth Strauss Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • UK Lung Cancer Coalition Professional groups • Association of Anaesthetists • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • Association of Surgeons of Great Britain and Ireland • Association for Cancer Surgery • British Geriatrics Society • British Institute of Radiology • British Oncology Pharmacy Association	General commentators • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Comparator companies • Accord Healthcare (pemetrexed, docetaxel, carboplatin, cisplatin, gemcitabine, paclitaxel, vinorelbine) • Aspire pharma (pemetrexed) • Boehringer Ingelheim (nintedanib) • Bristol Myers Squibb Pharmaceuticals (paclitaxel, nivolumab) • Eli Lilly and company (pemetrexed) • Genus pharmaceuticals (pemetrexed) • Hospira UK (carboplatin, docetaxel, gemcitabine, paclitaxel, cisplatin)

• British Psychosocial Oncology Society (BPOS) • British Thoracic Oncology Group • British Thoracic Society • Cancer Research UK • Lung Cancer Nursing UK • National Heart and Lung Institute • National Lung Cancer Forum for Nurses • Primary Care Respiratory Society • Royal College of Anesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health • NHS England • Welsh Government	• medac GmbH (vinorelbine) • Merck Sharp & Dohme (pembrolizumab) • Mylan (pemetrexed) • Pfizer (pemetrexed, bevacizumab) • Pierre Fabre (vinorelbine) • Roche (atezolizumab, bevacizumab) • Sandoz (pemetrexed, docetaxel) • Seacross pharmaceuticals (pemetrexed, docetaxel, paclitaxel) • Sun Pharmaceuticals (pemetrexed, gemcitabine) • Teva UK (paclitaxel) • Zentiva (pemetrexed, bevacizumab) <u>Relevant research groups</u> • British Association of Lung Research • Cochrane Airways Group • Cochrane Lung Cancer Group • Cochrane UK • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health & Care Research <u>Associated Public Health Groups</u> • UK Health Security Agency • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.